Circulating autoantibody to FOXP3 may be a potential biomarker for esophageal squamous cell carcinoma

Tumor Biology

Volumn 34, Issue 3, 2013, Pages 1873-1877

  Ye, Leiguang ^a   Guan, Songlei ^b   Zhang, Cong ^b   Lee, Kuang Hui ^c   Sun, Shilong ^b   Wei, Jun ^d   Liu, Baogang ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

^c Pei Ling Guan Si Hospital   (Taiwan)

^d UNIVERSITY OF THE HIGHLANDS AND ISLANDS   (United Kingdom)

Author keywords

Autoantibodies; Esophageal squamous cell carcinoma; FOXP3; Tumor immunity

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; HLA ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; TRANSCRIPTION FACTOR FOXP3;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 84878682698     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0729-8     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241-5.
3. Lam KY, Ma L. Pathology of esophageal cancers: local experience and current insights. Chin Med J (Eng). 1997;10:459-64.
4. Almhanna K, Strosberg JR. Multimodality approach for locally advanced esophageal cancer. World J Gastroenterol. 2012;18:5679-87.
5. Coffer PJ, Burgering BMT. Forkhead-box transcription factors and their role in the immune system. Nat Rev. 2004;4:889-99.
6. Redpath M, Xu B, van Kempen LC, Spatz A. The dual role of the X-linked FoxP3 gene in human cancers. Mol Oncol. 2011;5:156-63.
7. + T cells to T-regulatory cells. Cancer Res. 2011;71:3505-15.
8. Xu T, Duan Q, Wang G, Hu B. CD4 + CD25high regulatory T cell numbers and FOXP3 mRNA expression in patients with advanced esophageal cancer before and after chemotherapy. Cell Biochem Biophys. 2011;61:389-92.
9. Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grüssel S, Sipos B, et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism ofimmune evasion in cancer. Cancer Res. 2007;67:8344-50.
10. Ebert LM, Tan BS, Browning J, Svobodova S, Russell SE, Kirkpatrick N, et al. The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res. 2008;68:3001-9.
11. Karanikas V, Speletas M, Zamanakou M, Kalala F, Loules G, Kerenidi T, et al. Foxp3 expression in human cancer cells. J Transl Med. 2008;6:19.
12. Cunha LL, Morari EC, Nonogaki S, Soares FA, Vassallo J, Ward LS. Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas. Clinics (São Paulo, Brazil). 2012;67:483-8.
13. Triulzi T, Tagliabue E, Balsari A, Casalini P. FOXP3 expression in tumor cells and implications for cancer progression. J Cell Physiol. 2013;228:30-5.
14. Yoshii M, Tanaka H, Ohira M, Muguruma K, Iwauchi T, Lee T, et al. Expression of Forkhead box P3 in tumour cells causes immunoregulatory function of signet ring cell carcinoma of the stomach. Br J Cancer. 2012;106:1668-74.
15. Söllner J, Heinzel A, Summer G, Fechete R, Stipkovits L, Szathmary S, et al. Concept and application of a computational vaccinology workflow. Immunome Res. 2010;6 Suppl 2:S7.
16. Wang P, Sidney J, Kim Y, Sette A, Lund O, Nielsen M, et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinforma. 2010;11:568.
17. Liu L, Liu N, Liu B, Yang Y, Zhang Q, Zhang W, et al. Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer? J Cancer Res Clin Oncol. 2012;138:1737-42.
18. Guan S, Liu B, Zhang C, Lee K-H, Sun S, Wei J. Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma. Clin Transl Oncol. 2013. doi: 10.1007/s12094-013-1007-3.
19. Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol. 2007;18:868-73.
20. Tan HT, Low J, Lim SG, Chung MC. Serum autoantibodies as biomarkers for early cancer detection. FEBS J. 2009;276:6880-904.
21. Lam S, Boyle P, Healey GF, Maddison P, Peek L, Murray A, et al. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila). 2011;4:1126-34.
22. Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, et al. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol. 2012;33:1319-26.
23. Ranju R, Arora S, Chattopadhyay TK, Shukla NK, Mathur M. Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. Int J Cancer. 2000;86:791-5.
24. Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, et al. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer. 2000;89:1677-83.
25. Fujita Y, Nakanishi T, Hiramatsu M, Mabuchi H, Miyamoto Y, Miyamoto A, et al. Proteomics based approach identifying autoantibody against Peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res. 2006;12:6415-20.
26. Fujita Y, Nakanishi T, Miyamoto Y, Hiramatsu M, Mabuchi H, Miyamoto A, et al. Protemics based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Lett. 2008;263:280-90.
27. Dong J, Zeng B-H, Xu L-H, Wang J-Y, Li M-Z, Zeng M-S, et al. Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma. J Transl Med. 2010;8:81.
28. Zhou J-H, Zhang B, Kernstine KH, Zhong L. Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma. World J Gastroenterol. 2011;17:1373-8.